The Food and Drug Administration has approved Moderna’s mRNA flu vaccine, marking a significant public health advancement. This new vaccine leverages the mRNA technology developed during the COVID-19 pandemic and is expected to offer improved protection against the flu compared to the conventional vaccine, which has been in use for roughly 80 years.
The flu is a widespread and costly illness, responsible for approximately 1 billion infections and 300,000 deaths annually. A key challenge with traditional flu vaccines is the significant time lag in manufacturing, which typically takes six to eight months. This lengthy process often results in the vaccine being formulated based on virus strains that have already begun to mutate by the time the flu season arrives.
Moderna's mRNA vaccine operates differently. Instead of using weakened or inactivated viruses, it employs genetic instructions to train the immune system to target influenza. This method allows for a shorter manufacturing timeline, enabling the vaccine to be produced closer to the start of flu season. Clinical trials indicated that older adults who received Moderna's mRNA vaccine were 27 percent less likely to contract the flu than those who received the standard vaccine.
Public health experts express optimism about mRNA technology's potential. Beyond the new flu vaccine, researchers are exploring mRNA applications for vaccines against diseases such as malaria, tuberculosis, and HIV. However, for influenza, the ultimate goal remains a "universal flu vaccine." Such a vaccine would aim to be at least 75 percent effective against influenza A, the most virulent type of flu virus, and provide protection for at least one year.
The development of a universal flu vaccine faces the ongoing challenge of the virus's rapid mutation rate. Current flu vaccines, both conventional and mRNA-based, work by teaching the immune system to recognize the hemagglutinin protein on the virus. However, this protein is prone to frequent mutation. Researchers are pursuing strategies that target less mutable parts of the virus or aim to train the immune system to recognize multiple strains simultaneously. Several experimental vaccines utilizing these approaches are currently in clinical trials. If successful, these could potentially offer long-term protection, similar to the measles vaccine, eliminating the need for annual vaccinations.